LifeMD, Inc. (NASDAQ:LFMD) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in LifeMD, Inc. (NASDAQ:LFMD) by 12.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,155,193 shares of the company’s stock after acquiring an additional 128,701 shares during the quarter. Vanguard Group Inc. owned 2.83% of LifeMD worth $11,875,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in shares of LifeMD by 266.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after acquiring an additional 3,348 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in LifeMD in the fourth quarter valued at $117,000. Russell Investments Group Ltd. purchased a new position in shares of LifeMD in the fourth quarter valued at $153,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of LifeMD during the 4th quarter worth $173,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of LifeMD in the 1st quarter worth about $432,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. B. Riley restated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research report on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of LifeMD in a report on Friday, May 10th. BTIG Research boosted their price target on LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. KeyCorp decreased their price objective on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a research report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $12.17.

LifeMD Price Performance

LFMD stock opened at $5.51 on Wednesday. The stock has a market capitalization of $230.08 million, a price-to-earnings ratio of -7.45 and a beta of 1.24. The company has a quick ratio of 0.94, a current ratio of 0.99 and a debt-to-equity ratio of 10.83. LifeMD, Inc. has a 52-week low of $3.46 and a 52-week high of $12.88. The stock’s fifty day simple moving average is $6.82 and its 200-day simple moving average is $8.14.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same period last year, the business earned ($0.23) EPS. Equities research analysts expect that LifeMD, Inc. will post -0.25 EPS for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.